DAWN

Day One Biopharmaceuticals Inc

Add to Watchlist

Advanced Chart

7.230

+0.02(0.277%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

7.338

Open

7.270

VWAP

7.21

Vol

1.50M

Mkt Cap

732.85M

Low

7.065

Amount

10.81M

EV/EBITDA(TTM)

Total Shares

87.39M

259.83M

EV/OCF(TTM)

P/S(TTM)

Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. The Company’s commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. Its pipeline product candidates include DAY301 and VRK1 program. The DAY301 candidate is a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody (mAb), conjugated with a topoisomerase I inhibitor through a stable and hydrophilic modified valine-alanine (VA) cleavable linker. Its VRK1 program is a novel target involved in the regulation of cell division and DNA damage repair.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

34.94M

+326.52%

-0.351

+602.38%

39.63M

-57.73%

-0.327

-186.09%

-0.326

-48.29%

Estimates Revision

The market is revising Downward the revenue expectations for Day One Biopharmaceuticals, Inc. (DAWN) for FY2025, with the revenue forecasts being adjusted by -3.55% over the past three months. During the same period, the stock price has changed by -6.59%.

Revenue Estimates for FY2025

Revise Downward

-3.55%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-15.22%

In Past 3 Month

Stock Price

Go Down

-6.59%

In Past 3 Month

8 Analyst Rating

289.21% Upside

Wall Street analysts forecast DAWN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DAWN is 28.14 USD with a low forecast of 20.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

1 Hold

0 Sell

Strong Buy

289.21% Upside

Current: 7.230

Low

20.00

Averages

28.14

High

36.00

289.21% Upside

Current: 7.230

Low

20.00

Averages

28.14

High

36.00

HC Wainwright & Co.

Andres Maldonado

Strong Buy

Reiterates

$36

2025-04-03

Reason

HC Wainwright & Co.

Andres Maldonado

Price Target

$36

2025-04-03

Reiterates

Strong Buy

Reason

Goldman Sachs

Andrea Tan

Strong Buy

Maintains

$39 → $27

2025-03-25

Reason

Goldman Sachs

Andrea Tan

Price Target

$39 → $27

2025-03-25

Maintains

Strong Buy

Reason

JP Morgan

Anupam Rama

Buy

Maintains

$39 → $34

2025-03-05

Reason

JP Morgan

Anupam Rama

Price Target

$39 → $34

2025-03-05

Maintains

Buy

Reason

JPMorgan analyst Anupam Rama lowered the firm's price target on Day One Biopharmaceuticals to $34 from $39 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group.

Needham

Ami Fadia

Strong Buy

Reiterates

$32

2025-02-26

Reason

Needham

Ami Fadia

Price Target

$32

2025-02-26

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Andres Maldonado

Strong Buy

Maintains

$40 → $36

2025-02-26

Reason

HC Wainwright & Co.

Andres Maldonado

Price Target

$40 → $36

2025-02-26

Maintains

Strong Buy

Reason

Wedbush

Robert Driscoll

Buy

Reiterates

$32

2025-02-26

Reason

Wedbush

Robert Driscoll

Price Target

$32

2025-02-26

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Day One Biopharmaceuticals Inc (DAWN.O) is -5.54, compared to its 5-year average forward P/E of -8.09. For a more detailed relative valuation and DCF analysis to assess Day One Biopharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.09

Current PE

-5.54

Overvalued PE

-4.69

Undervalued PE

-11.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.44

Current EV/EBITDA

-1.69

Overvalued EV/EBITDA

-0.98

Undervalued EV/EBITDA

-9.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

519.41

Current PS

4.23

Overvalued PS

2444.38

Undervalued PS

-1405.57

Financials

Annual

Quarterly

FY2025Q1

30.76M

Total Revenue

FY2025Q1

YoY :

-38.49%

-41.07M

Operating Profit

FY2025Q1

YoY :

-42.33%

-36.00M

Net Income after Tax

FY2025Q1

YoY :

-51.39%

-0.35

EPS - Diluted

FY2025Q1

YoY :

+26.31%

-62.81M

Free Cash Flow

FY2025Q1

90.62

Gross Profit Margin - %

FY2025Q1

N/A

FCF Margin - %

FY2025Q1

-117.02

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

167.2K

USD

3-6

Months

252.0K

USD

6-9

Months

701.0K

USD

0-12

Months

697.1K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.3M

Volume

6-9

Months

3.2M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.2M

Volume

Months

6-9

1.2M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

167.2K

USD

3-6

Months

252.0K

USD

6-9

Months

701.0K

USD

0-12

Months

697.1K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

DAWN News & Events

Events Timeline

2025-06-10 (ET)

2025-06-10

08:40:57

Day One Biopharmaceuticals appoints Michael Vasconcelles as Head of R&D

2025-05-06 (ET)

2025-05-06

16:18:25

Day One Biopharmaceuticals reports Q1 EPS (35c), consensus (44c)

2025-02-25 (ET)

2025-02-25

16:20:45

Day One Biopharmaceuticals reports Q4 EPS ($1.02), consensus (35c)

News

3.0

07-07NASDAQ.COM

DAY ONE BIOPHARMACEUTICALS Earnings Preview: Recent $DAWN Insider Trading, Hedge Fund Activity, and More

5.0

06-10Newsfilter

Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

3.0

05-05Yahoo Finance

Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Report Preview: What to Expect

People Also Watch

Ocular Therapeutix Inc

Coastal Financial Corp (EVERETT)

Kennedy-Wilson Holdings Inc

Loma Negra Compania Industrial Argentina SA

UP Fintech Holding Ltd

Delek US Holdings Inc

22.690

USD

+0.44%

FAQ

What is Day One Biopharmaceuticals Inc (DAWN) stock price today?

The current price of DAWN is 7.23 USD — it has increased 0.28 % in the last trading day.

DAWN

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

DAWN News & Events

Events Timeline

News

People Also Watch

FAQ

What is Day One Biopharmaceuticals Inc (DAWN) stock price today?

What is Day One Biopharmaceuticals Inc (DAWN)'s business?

What is the price predicton of DAWN Stock?

What is Day One Biopharmaceuticals Inc (DAWN)'s revenue for the last quarter?

What is Day One Biopharmaceuticals Inc (DAWN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Day One Biopharmaceuticals Inc (DAWN)'s fundamentals?

How many employees does Day One Biopharmaceuticals Inc (DAWN). have?

What is Day One Biopharmaceuticals Inc (DAWN) market cap?